Economics of Innovation - OHE

OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.

OHE staff recently attended the ISPOR Europe 2018 conference in Barcelona. In this blog post, we share a selection of our presentations.

Budget Impact and Expenditure Caps: Potential or Pitfall? from Office of Health Economics

The debate on indication-based pricing from Office of Health Economics

What Does Patient-centred Care Mean for Medicine in the Welfare States of Europe: A Response to Peter Zweifel from Office of Health Economics

HTA Value Based Pricing Versus WHO Fair Pricing: Which Delivers Universal Health Coverage? from Office of Health Economics

Global Pharmaceutical Innovation – Too Much, Too Little or Both? from Office of Health Economics

Payment Mechanisms and handling Uncertainty from Office of Health Economics

Establishing an Aligned View of a Modern Forward-looking HTA Process from Office of Health Economics

Should Drug Prices Differ by Indication? Outlining the debate on indication-based pricing and how it has been implemented to date from Office of Health Economics

News & Insights

Latest Research & Publications

Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment

Evaluating the Cost-effectiveness of Health System Strengthening: A Platforms Perspective

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

2018 OHE Annual Report to the Charity Commission

HTA and Payment Mechanisms for New Drugs to Tackle AMR

All Publications

Share on Mastodon